Combination chemotherapy for hepatitis B virus: The final solution?

Hepatology

Volumn 32, Issue 2, 2000, Pages 430-432

  Shaw, Tim ^a   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO; RIBAVIRIN; VIRUS DNA;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER HISTOLOGY; PRIORITY JOURNAL; VIREMIA; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD;

EID: 0033859683     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.16181     Document Type: Article

References (37)

1. Update on diagnosis, management, and prevention of hepatitis B virus infection
2. Perspectives for the treatment of hepatitis B virus infections
3. The identification and development of anti-viral agents for the treatment of chronic hepatitis B virus infection
4. Hepatic purine and pyrimidine metabolism: Implications for antiviral chemotherapy of viral hepatitis
5. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa
6. Combination chemotherapy for HBV: The way forward?
7. Hepatitis B virus replication-An update
8. Lamivudine as initial treatment for chronic hepatitis B in the United States
9. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
10. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
11. Famciclovir treatment of anti-HBe+ chronic hepatitis B: Results of a randomized, placebo-controlled study
12. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
13. Comparative biology and pathogenesis of AIDS and hepatitis B viruses: Related but different
14. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
15. Combination therapy for chronic hepatitis B
16. A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance
17. Update on highly active antiretroviral therapy: Progress and strategies
18. Human immunodeficiency virus drug resistance testing: State of the art in genotypic and phenotypic testing of antiretrovirals
19. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
20. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
21. Hepatitis B virus replication and mutation are autoregulated by interactions between surface antigen and HBeAg and the HBV DNA polymerase: A functional model with therapeutic implications
22. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
23. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
24. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
25. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA
26. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
27. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B
28. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
29. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir
30. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks
31. The dynamics of hepatitis B virus infection
32. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
33. A randomized, placebo-controlled trial to evaluate the efficacy of twelve-month famciclovir treatment in patients with chronic HBeAg-positive hepatitis B
34. In vitro evaluation of hepatitis B. virus polymerase mutations associated with famciclovir resistance
35. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: A viral dynamics study
36. Debates in hepatitis: How to assess HBV DNA reductions in association with therapy
37. Line probe assay for monitoring drug resistance in hepatitis B virus- infected patients during antiviral therapy